Cardinal Health, Inc.

Cardinal holds multi-year distribution agreements with approximately 85% of U.S. hospitals and more than 26,000 pharmacies, providing solid contract-based forward visibility. However, the loss of the OptumRx contracts at the end of FY2024 (17% of FY2024 consolidated revenue) demonstrates that large distribution agreements carry meaningful renewal risk.

The Pharmaceutical and Specialty Solutions segment generated $204.6B of $222.6B in FY2025 consolidated revenue, representing approximately 92% of the total, with GMPD contributing less than 8% and the Other segment the remainder. Structural concentration in a single service category is substantial, even if day-to-day demand across thousands of products is diversified.

The pharmaceutical distribution business is almost entirely U.S.-based; GMPD sells into Canada, Europe, and Asia, but the dominant $204.6B pharma revenue stream is overwhelmingly domestic. This leaves Cardinal fully exposed to U.S. drug pricing regulation, reimbursement reform, and domestic demand dynamics.

Core pharmaceutical distribution is a logistics-intensive business requiring additional warehouse capacity, compliance infrastructure, and personnel to support incremental volume, limiting structural operating leverage. The nuclear and at-home segments offer better unit economics, but together they represent a small share of total revenue.

Drug distribution is transactional but mission-critical: hospitals cannot defer pharmaceutical procurement, and Cardinal's specialty and nuclear businesses serve physicians and hospitals with limited substitutability. The exit of the lower-margin OptumRx bulk business modestly shifted the remaining revenue mix toward branded, specialty, and contractual channels.